Which HIV prevention shot do patients prefer? new study aims to find out

NCT ID NCT07379658

Not yet recruiting Knowledge-focused Sponsor: Anupama Raghuram MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will survey 128 adults in Louisville, Kentucky who are already taking or starting a long-acting injectable HIV PrEP shot. Participants will answer questionnaires about their satisfaction and adherence to either lenacapavir or cabotegravir over 12 months. The goal is to understand real-world preferences and outcomes, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors and patients choose the long-acting injectable PrEP that works best for them, improving HIV prevention.
What could go wrong: This is an observational study, not a treatment trial. It only measures satisfaction and adherence, not whether the drugs prevent HIV better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PRE-EXPOSURE PROPHYLAXIS

Contacts and locations

Locations

Norton Healthcare

Louisville, Kentucky, 40202, United States
University of Louisville, Kent School of Social Work

Louisville, Kentucky, 40292, United States
University of Louisville, School of Public Health and Information Sciences

Louisville, Kentucky, 40202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.